目前治疗勃起功能障碍的方法:系统性审查和元分析的综合性审查
Jian Ma1, Jintao Wei1, Jinze Li1
1TCM Requlating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
目前的勃起功能障碍 (ED) 治疗显示出统计学上显著的改善,但证据质量较低. 需要更多高质量的研究来可靠地评估ED治疗的有效性.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 基于证据的医学基于证据的医学.
- 临床药理学 临床药理学
背景情况:
- 在全球范围内,勃起功能障碍 (ED) 影响了大量男性.
- 治疗ED的风景是多样化的,包括药理和非药理干预措施.
- 评估这些治疗方法的有效性和证据质量对于临床实践至关重要.
研究的目的:
- 进行总体审查,总结和评估当前勃起功能障碍 (ED) 治疗的有效性.
- 评估支持ED干预的证据的整体质量.
主要方法:
- 系统地搜索主要数据库 (PubMed,科学网,科克伦图书馆,Embase) 到2025年10月.
- 从专注于ED治疗的已发表的元分析中提取数据.
- 使用AMSTAR-2标准评估元分析质量,评估总结效果质量.
主要成果:
- 分析了23个元分析,涵盖了36个干预措施,产生了42个总结效应.
- 大多数元分析 (87%) 被评为极低或低质量的.
- 大多数总结效应 (95.2%) 被评为质量低或非常低,只有两个被评为质量中等或高.
结论:
- 目前勃起功能障碍 (ED) 治疗的证据基础主要是低质量或非常低质量的.
- 由于研究的局限性,观察到的ED症状的改善需要谨慎解释.
- 迫切需要高质量的研究,包括精心设计的研究和元分析,以提高ED治疗证据的可靠性.
更多相关视频
09:49Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
03:51Author Spotlight: Advanced Treatment of Seminal Duct Blockage Employing Endoscopy-Mediated Semen Channel Refluviation
Published on: December 8, 2023
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Male Sexual Response: Erection & Ejaculation
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
